Ongoing projects

  • The Norwegian Registry of Persons Assessed for Cognitive Symptoms in Specialist Health Care Services (NorCog)
  • Trajectories in real life and risk factors of dementia (Trail-Dem)
  • Importance of low-grade inflammation in patients with cognitive impairment due to Alzheimer’s disease and stroke (Inflamdem)
  • Qualitative EEG as a prognostic tool in mild cognitive impairment (NORD-MCI)
  • Disentangle subtypes of Alzheimer’s disease using structural MRI modalities- a cross-sectional and longitudinal study (SAS-MRI study)
  • Spatial orientation in persons with mild cognitive impairment and Alzheimer’s disease
  • Repeated advanced cognitive training in mild cognitive impairment (REACT-MCI)
  • Mechanisms of increased susceptibility to Alzheimer’s disease in women – FEMDEM
  • The crosstalk of mitochondrial dysfunction, inflammation, and genotypes in the insidious onset of neurodegenerative dementia disorders (MITO-DEM)
  • Improving dementia diagnostics in clinical practice using artificial intelligence (AIDDEM)
  • Neutrophil extracellular traps (NETs) in Alzheimer’s disease: deciphering pathophysiology in the search for novel biomarkers and treatment targets.
  • The Norwegian cognitive impairment after stroke study (Nor-COAST)

Clinical trials (2023-2026)

  • REACT-MCI - repeated advanced cognitive training in mild cognitive impairment. In REACT-MCI we study whether advanced memory training can improve memory and quality of life in patients with mild cognitive impairment (MCI). For more information, see the study webpage (in Norwegian)
  • The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB). In the ANeED clinical trial we investigate if the mediciation ambroxol has a treatment effect for cognitive impairment or dementia caused by Lewy body disease. Included patients have to be at an early disease stage. For more information, see the study webpage at Helse Fonna (in Norwegian) 
  • The EVOKE-study (a research study investigating semaglutide in people with early Alzheimer’s disease). In EVOKE we study whether the medicine semaglutide can slow the progression of Alzheimer’s disease at an early disease stage. Recruitment for EVOKE is completed. For more information, see the study webpage at Akershus universitetssykehus HF (in Norwegian)
 
Scroll to top